JP2025027013A5 - - Google Patents
Info
- Publication number
- JP2025027013A5 JP2025027013A5 JP2024205131A JP2024205131A JP2025027013A5 JP 2025027013 A5 JP2025027013 A5 JP 2025027013A5 JP 2024205131 A JP2024205131 A JP 2024205131A JP 2024205131 A JP2024205131 A JP 2024205131A JP 2025027013 A5 JP2025027013 A5 JP 2025027013A5
- Authority
- JP
- Japan
- Prior art keywords
- application
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056569P | 2014-09-28 | 2014-09-28 | |
| US62/056,569 | 2014-09-28 | ||
| US201562129883P | 2015-03-08 | 2015-03-08 | |
| US62/129,883 | 2015-03-08 | ||
| JP2020207244A JP7168641B2 (ja) | 2014-09-28 | 2020-12-15 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
| JP2022172033A JP7668257B2 (ja) | 2014-09-28 | 2022-10-27 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172033A Division JP7668257B2 (ja) | 2014-09-28 | 2022-10-27 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025027013A JP2025027013A (ja) | 2025-02-26 |
| JP2025027013A5 true JP2025027013A5 (enExample) | 2025-09-30 |
Family
ID=55582160
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516664A Active JP6811711B2 (ja) | 2014-09-28 | 2015-09-28 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
| JP2020207244A Active JP7168641B2 (ja) | 2014-09-28 | 2020-12-15 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
| JP2022172033A Active JP7668257B2 (ja) | 2014-09-28 | 2022-10-27 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
| JP2024205131A Pending JP2025027013A (ja) | 2014-09-28 | 2024-11-26 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516664A Active JP6811711B2 (ja) | 2014-09-28 | 2015-09-28 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
| JP2020207244A Active JP7168641B2 (ja) | 2014-09-28 | 2020-12-15 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
| JP2022172033A Active JP7668257B2 (ja) | 2014-09-28 | 2022-10-27 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10428143B2 (enExample) |
| EP (1) | EP3197495A4 (enExample) |
| JP (4) | JP6811711B2 (enExample) |
| KR (3) | KR102506663B1 (enExample) |
| CN (1) | CN106999585A (enExample) |
| AU (3) | AU2015319809B2 (enExample) |
| CA (1) | CA2961950A1 (enExample) |
| EA (1) | EA034921B1 (enExample) |
| IL (4) | IL283834B (enExample) |
| MX (2) | MX388410B (enExample) |
| WO (1) | WO2016049641A1 (enExample) |
| ZA (1) | ZA201701658B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201604738TA (en) | 2013-12-12 | 2016-07-28 | Shanghai Hengrui Pharm Co Ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| CA2955086A1 (en) | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| KR102506663B1 (ko) * | 2014-09-28 | 2023-03-08 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 자극성 및 비자극성 골수성 세포의 조절 |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| SG11201901611YA (en) | 2016-08-31 | 2019-03-28 | Agency Science Tech & Res | Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof |
| EP3516396B1 (en) * | 2016-09-26 | 2024-11-13 | F. Hoffmann-La Roche AG | Predicting response to pd-1 axis inhibitors |
| WO2018147291A1 (en) | 2017-02-07 | 2018-08-16 | Saitama Medical University | Immunological biomarker for predicting clinical effect of cancer immunotherapy |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| CN107267555B (zh) * | 2017-05-27 | 2020-03-20 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用 |
| CA3061755A1 (en) * | 2017-08-03 | 2019-02-07 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| EP3664845A4 (en) * | 2017-08-08 | 2021-03-10 | Pionyr Immunotherapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEACTIVATING MEYLOID CELLS EXPRESSING TREM1 |
| CA3079999A1 (en) * | 2017-11-07 | 2019-05-16 | The Board Of Regents Of The University Of Texas System | Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer |
| BR112020009759A8 (pt) | 2017-11-17 | 2023-01-31 | Merck Sharp & Dohme | Anticorpos específicos para transcrito 3 semelhante à imunoglobulina (ilt3) e usos dos mesmos |
| MX2020006213A (es) * | 2017-12-12 | 2020-09-14 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y metodos relacionados. |
| CN108085393B (zh) * | 2018-01-31 | 2020-06-02 | 青岛泱深生物医药有限公司 | 肾透明细胞癌相关生物标志物及其应用 |
| JP2021511812A (ja) * | 2018-02-02 | 2021-05-13 | オンコイミューン， インコーポレイテッド | がん治療のためのより安全でより効果的な抗ｃｔｌａ４抗体を選択及び設計する方法 |
| CA3101139A1 (en) * | 2018-06-21 | 2020-01-02 | Faron Pharmaceuticals Oy | Treatment of cancer with clever-1 inhibition in combination with pd-1/pd-l1 inhibitor |
| AU2019295409B2 (en) | 2018-06-25 | 2025-09-04 | Peter Maccallum Cancer Institute | Modified T cells and uses thereof |
| UY38407A (es) * | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| WO2020097193A1 (en) | 2018-11-06 | 2020-05-14 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| KR20210104079A (ko) * | 2018-12-11 | 2021-08-24 | 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 | 항-trem2 항체를 사용하는 방법 |
| CN109609463B (zh) * | 2019-01-10 | 2022-07-01 | 中国医学科学院肿瘤医院 | 一种宫颈癌肿瘤原代细胞分离及培养方法 |
| US10836828B2 (en) | 2019-02-06 | 2020-11-17 | Pionyr Immunotherapeutics, Inc. | Anti-TREM1 antibodies and related methods |
| WO2020171141A1 (ja) * | 2019-02-20 | 2020-08-27 | 学校法人 埼玉医科大学 | がん免疫療法における長期生存を予測するための方法および組成物 |
| TW202035702A (zh) | 2019-02-20 | 2020-10-01 | 學校法人埼玉醫科大學 | 評價藉由放射線治療之抗腫瘤免疫效果之末梢血液生物標記 |
| PE20211979A1 (es) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc | Anticuerpos anti-trem2 y metodos para utilizarlos |
| US11026973B2 (en) | 2019-04-30 | 2021-06-08 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| US20220313840A1 (en) * | 2019-06-04 | 2022-10-06 | Academia Sinica | Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors |
| WO2021029318A1 (ja) * | 2019-08-13 | 2021-02-18 | 国立大学法人東北大学 | 免疫チェックポイント阻害剤、免疫チェックポイント関連疾患の治療剤、免疫抑制剤、抗フィブロネクチン抗体又はその誘導体、フィブロネクチンアナログ、フィブロネクチンまたはその部分タンパク質を検出するためのキット、及びフィブロネクチンまたはその部分タンパク質を検出する方法 |
| GB2628935B (en) | 2019-09-03 | 2025-03-05 | Myeloid Therapeutics Inc | Methods and compositions for genomic integration |
| CN110836974B (zh) * | 2019-11-07 | 2022-09-09 | 西安交通大学医学院第一附属医院 | Flt3lg蛋白在制备肺腺癌术后预后评估试剂或者试剂盒中的应用 |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| BR112022011790A2 (pt) | 2019-12-19 | 2022-08-30 | Ngm Biopharmaceuticals Inc | Agentes de ligação a ilt3 e métodos de uso dos mesmos |
| JP2023512450A (ja) | 2020-01-13 | 2023-03-27 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| IL272390A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Cancer treatment methods |
| EP4136114A1 (en) | 2020-04-14 | 2023-02-22 | Les Laboratoires Servier | Anti-flt3 antibodies and compositions |
| WO2022057910A1 (en) * | 2020-09-17 | 2022-03-24 | I-Mab Biopharma Co., Ltd | Combination therapies targeting c5ar and pd-1/pd-l1 pathways |
| WO2022098905A2 (en) | 2020-11-04 | 2022-05-12 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| US11617767B2 (en) | 2020-11-20 | 2023-04-04 | Simcere Innovation, Inc. | Armed dual CAR-T compositions and methods for cancer immunotherapy |
| GB2620502A (en) * | 2021-03-09 | 2024-01-10 | Mascarenhas Desmond | Modulation of mammalian cell lineage by synthetic immodulins |
| WO2022197949A2 (en) | 2021-03-17 | 2022-09-22 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| AU2022272235A1 (en) | 2021-05-11 | 2023-12-21 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| MX2024003039A (es) * | 2021-09-08 | 2024-04-19 | Biocad Joint Stock Co | Anticuerpo quimerico, biespecifico, bivalente que comprende un heterodimero basado en cmh o proteinas similares a cmh. |
| KR20240091056A (ko) | 2021-10-28 | 2024-06-21 | 길리애드 사이언시즈, 인코포레이티드 | 피리디진-3(2h)-온 유도체 |
| WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2023094436A1 (en) * | 2021-11-26 | 2023-06-01 | Technische Universität Dresden | Placental macrophages for cell therapy |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| JP2024545193A (ja) | 2021-12-22 | 2024-12-05 | ギリアード サイエンシーズ， インコーポレイテッド | Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| US12358887B2 (en) | 2022-03-17 | 2025-07-15 | Gilead Sciences, Inc. | IKAROS Zinc Finger Family degraders and uses thereof |
| CN119487038A (zh) | 2022-04-21 | 2025-02-18 | 吉利德科学公司 | Kras g12d调节化合物 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250101101A1 (en) | 2023-09-01 | 2025-03-27 | iTeos Belgium SA | Anti-trem2 antibodies and methods of use |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| JPH08500962A (ja) | 1992-02-06 | 1996-02-06 | クリエイティブ バイオモレキュルズ，インコーポレイテッド | 癌マーカー用生物合成結合蛋白質 |
| US7294331B2 (en) | 1994-03-07 | 2007-11-13 | Immunex Corporation | Methods of using flt3-ligand in hematopoietic cell transplantation |
| DE19638745C2 (de) * | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US7442777B2 (en) | 2000-11-29 | 2008-10-28 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US8231878B2 (en) * | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
| US20070213660A1 (en) | 2004-10-29 | 2007-09-13 | Mark Richards | Fibrin sealant delivery device including pressure monitoring, and method and kits thereof |
| AU2006230413B8 (en) | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
| WO2006138005A2 (en) | 2005-05-10 | 2006-12-28 | Monsanto Technology, Llc | Genes and uses for plant improvement |
| JP5372500B2 (ja) | 2005-06-17 | 2013-12-18 | トレラクス リクイデーティング トラスト | Ｉｌｔ３結合分子およびその使用 |
| WO2007089945A2 (en) * | 2006-02-02 | 2007-08-09 | The Trustees Of Columbia University In The City Of New York | Treating diseases by targeting silt3 |
| EP2041180B8 (en) | 2006-06-19 | 2014-03-05 | Liquidating Trust | Ilt3 binding molecules and uses therefor |
| NZ582150A (en) * | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| WO2010141566A1 (en) | 2009-06-03 | 2010-12-09 | Immunogen, Inc. | Conjugation methods |
| ES2609043T3 (es) | 2009-11-30 | 2017-04-18 | Janssen Biotech, Inc. | Anticuerpos mutantes Fc con funciones de efecto abladas |
| CA2785964C (en) | 2009-12-29 | 2021-03-30 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd27 antibody |
| CA2793657A1 (en) * | 2010-03-18 | 2011-09-22 | Colorado State University Research Foundation | Myeloid derived suppressor cell inhibiting agents |
| BR112012024489A2 (pt) | 2010-03-29 | 2016-05-31 | Zymeworks Inc | anticorpos com função efetora suprimida ou aumentada |
| US20110262348A1 (en) | 2010-03-29 | 2011-10-27 | Vrije Universiteit Brussel | Selective targeting of intratumoral cells |
| US20140045915A1 (en) * | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| US8427899B2 (en) * | 2010-10-29 | 2013-04-23 | Taiwan Semiconductor Manufacturing Company, Ltd. | Self-adaptive sensing design |
| KR20160044598A (ko) | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| WO2012149416A2 (en) * | 2011-04-28 | 2012-11-01 | University Of Southern California | Human myeloid derived suppressor cell cancer markers |
| US9696312B2 (en) | 2011-09-02 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand |
| CA2877081C (en) | 2011-09-27 | 2020-09-22 | The Governing Council Of The University Of Toronto | Molecular display method |
| JP6411333B2 (ja) * | 2012-05-24 | 2018-10-24 | ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ | 腫瘍関連マクロファージのターゲティングおよびｉｎｖｉｖｏイメージング用抗マクロファージマンノース受容体単一可変ドメイン |
| US20150191543A1 (en) | 2012-08-06 | 2015-07-09 | The Regents Of The University Of California | Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
| BR112015010436A2 (pt) | 2012-11-07 | 2017-08-22 | Pfizer | Anticorpos anti-notch3 e conjugados anticorpo-fármaco |
| WO2014074942A1 (en) | 2012-11-08 | 2014-05-15 | Illumina, Inc. | Risk variants of alzheimer's disease |
| CA2894689A1 (en) * | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | Anti-human b7-h4 antibodies and their uses |
| US9617266B2 (en) * | 2013-03-05 | 2017-04-11 | Merck Patent Gmbh | Imidazopyrimidine derivatives |
| GB201311487D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
| US20160220692A1 (en) * | 2013-09-09 | 2016-08-04 | The Johns Hopkins University | Targeting the m2-tumor associated macrophage for cancer therapy |
| DK3089994T3 (da) * | 2013-12-30 | 2022-07-04 | Epimab Biotherapeutics Inc | Fabs-in-tandem-immunglobulin og anvendelser deraf |
| CA2955086A1 (en) * | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| KR102506663B1 (ko) | 2014-09-28 | 2023-03-08 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 자극성 및 비자극성 골수성 세포의 조절 |
| US20170334977A1 (en) | 2014-10-20 | 2017-11-23 | The Brigham And Women's Hospital, Inc. | Targeting Apolipoprotein E (APOE) in Neurologic Disease |
| CA2972048C (en) * | 2014-12-22 | 2023-03-07 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
| WO2017058866A1 (en) | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| WO2017062672A2 (en) | 2015-10-06 | 2017-04-13 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| AU2017300040A1 (en) | 2016-07-22 | 2019-01-24 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | TREM2 cleavage modulators and uses thereof |
| US10167796B2 (en) | 2017-05-17 | 2019-01-01 | GM Global Technology Operations LLC | Gasoline particulate filter regeneration strategy |
| AU2018307877A1 (en) | 2017-07-27 | 2020-01-02 | Novartis Ag | Sheddase resistant TREM2 variants |
| CA3061755A1 (en) | 2017-08-03 | 2019-02-07 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| CA3075285A1 (en) | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| MX2020006213A (es) | 2017-12-12 | 2020-09-14 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y metodos relacionados. |
| KR20210104079A (ko) | 2018-12-11 | 2021-08-24 | 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 | 항-trem2 항체를 사용하는 방법 |
-
2015
- 2015-09-28 KR KR1020177011420A patent/KR102506663B1/ko active Active
- 2015-09-28 JP JP2017516664A patent/JP6811711B2/ja active Active
- 2015-09-28 KR KR1020247012684A patent/KR20240056629A/ko active Pending
- 2015-09-28 IL IL283834A patent/IL283834B/en unknown
- 2015-09-28 AU AU2015319809A patent/AU2015319809B2/en active Active
- 2015-09-28 KR KR1020237007310A patent/KR102659538B1/ko active Active
- 2015-09-28 IL IL294043A patent/IL294043B2/en unknown
- 2015-09-28 EP EP15844518.9A patent/EP3197495A4/en active Pending
- 2015-09-28 WO PCT/US2015/052682 patent/WO2016049641A1/en not_active Ceased
- 2015-09-28 CN CN201580064906.2A patent/CN106999585A/zh active Pending
- 2015-09-28 EA EA201790755A patent/EA034921B1/ru unknown
- 2015-09-28 IL IL312777A patent/IL312777A/en unknown
- 2015-09-28 MX MX2017004007A patent/MX388410B/es unknown
- 2015-09-28 US US15/514,471 patent/US10428143B2/en active Active
- 2015-09-28 CA CA2961950A patent/CA2961950A1/en active Pending
-
2017
- 2017-03-08 ZA ZA2017/01658A patent/ZA201701658B/en unknown
- 2017-03-08 IL IL251020A patent/IL251020B/en active IP Right Grant
- 2017-03-27 MX MX2021014448A patent/MX2021014448A/es unknown
-
2019
- 2019-07-01 US US16/459,589 patent/US11325973B2/en active Active
-
2020
- 2020-01-30 AU AU2020200678A patent/AU2020200678B2/en active Active
- 2020-12-15 JP JP2020207244A patent/JP7168641B2/ja active Active
-
2022
- 2022-04-05 US US17/714,051 patent/US20220411496A1/en active Pending
- 2022-04-26 AU AU2022202730A patent/AU2022202730B2/en active Active
- 2022-10-27 JP JP2022172033A patent/JP7668257B2/ja active Active
-
2024
- 2024-11-26 JP JP2024205131A patent/JP2025027013A/ja active Pending